Search Results for: The New Industry Paradigm for
Articles
DELIVERY DEVICES - The New Industry Paradigm for Prefilled Success March 12, 2013
Alan Shortall indicates that following a period of relative industry stability defined by peripheral innovation, a converging series of external and internal forces are set to reshape the prefilled syringe industry so that it will better serve the emerging needs of pharmaceutical companies, patients, and other stakeholders across the continuum of care.
NJIT Researchers Unlock a New Method for Testing Protein-Based Drugs September 28, 2022
New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a “paradigm shift” in how...AREV Life Sciences Advances Developments, New Appointments & Relationships February 17, 2022
AREV Life Sciences Global Corp. recently announced its new corporate acquisitions and maturation of multiple product lines that are being...SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive & Untreatable Tumors February 9, 2022
SEngine Precision Medicine Inc. and Oncodesign recently announced the signature of a research collaboration agreement for R&D of a new personalized cancer treatment for aggressive and…..
Two New Studies Demonstrate In Vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane to Prevent Pathological Processes Underlying Osteoarthritis & Tendinopathy November 1, 2021
MiMedx Group, Inc. recently announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion chorion membrane (mdHACM) for...Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform October 22, 2021
Quris recently launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans – significantly improving efficacy and cutting drug development….
Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration With Site Sponsors June 23, 2021
Syneos Health recently expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for….
Proveris Scientific Research Collaboration: New Generation Technologies for Improved Measurement of Pharmaceutical Aerosols October 7, 2020
Proveris Scientific Corporation recently announced its research collaboration with The University of Sydney and Macquarie University on a project to develop a new generation of technologies for improving….
Metrion Biosciences & International Scientific Consortium Publish Data & New Recommendations for In Vitro Risk Assessment of the Cardiac Safety of New Medicines April 9, 2020
Metrion Biosciences Limited announced it has contributed to two new peer-reviewed papers under the US FDA CiPA (Comprehensive in vitro...BIOPROCESSING - A New Era: Why the Time Has Come for Biopharma to Move to Continuous Bioprocessing January 13, 2020
Dr. Martin Smith explains why the pharma industry must embrace continuous processing if it’s to survive and thrive in an era of global personalized medicine.
Prostate Cancer Treatment Moving Toward Personalized Approach With 6 New Drugs in the Pipeline August 14, 2019
Although options for prostate cancer have historically been limited, the late-stage prostate cancer pipeline holds promise for the future of...THERAPEUTIC FOCUS - Targeting the Novel LANCL2 Pathway Offers Potential for a Differentiated Treatment Paradigm for Autoimmune Diseases April 1, 2019
Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.
Procarta Announces Significant Investment for New Class of Antibiotics March 7, 2019
Procarta Biosystems recently announced $1.7 million of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR).
Saama Partners With The Leukemia & Lymphoma Society & Unveils New Capabilities for Award-Winning Life Science Analytics Cloud February 21, 2019
Saama Technologies, Inc. recently announced a new partnership with The Leukemia & Lymphoma Society (LLS), the world’s largest nonprofit dedicated...CELL CULTURE MARKET - 3D Cell Cultures: Next Generation & New Challenges November 19, 2015
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.
INDUSTRY PERSPECTIVES - The Future of the Pharma & Biotech Industries: Your Colleague’s Perspectives June 30, 2015
The Global Formulation Report in this issue provided some interesting data on what has been happening in a number of key sectors over the past 18 months. We thought it would be intriguing to hear what some of your colleagues believe will have a significant impact on the Pharma and Biotech industries throughout the next 5 to 10 years.
Credence MedSystems' Innovative Companion Safety Syringe System Earns Multiple Industry Awards March 2, 2015
Credence MedSystems’ Innovative Companion Safety Syringe System Earns Multiple Industry Awards Credence MedSystems, Inc. recently announced the Credence Companion Safety...MARKET ANALYSIS - Unprecedented Uptake of Sovaldi & Tecfidera Paves the Way for New Optimism in Pharma November 17, 2014
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, believes a successful drug launch is pivotal in the corporate evolution of most innovative drug companies, allowing them to sustain growth momentum, or, as is more commonplace in the age of the blockbuster patent expiration, replenish existing revenues at risk from lower-cost equivalents.
Novartis Expects 14 New Blockbusters November 8, 2012
Novartis recently provided an update on its leading Research and Development (R&D) pipeline and plans for turning these assets into...OrganaBio Launches On-Demand GMP-Compliant Hematopoietic Stem Cell Source for Advanced Therapy Manufacturing April 3, 2024
OrganaBio recently announced the launch of HematoPAC-HSC-CB-GMP, on-demand current good manufacturing practice (cGMP)-compliant CD34+ hematopoietic stem cells (HSCs) ethically derived...
